GO
Loading...

Allergan Inc

More

  • July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, on Monday announced 1,500 jobs cuts as part of a $475 million restructuring meant to boost profits over the next six years.

  • Cramer's stocks to watch: AGN & VRX     Monday, 21 Jul 2014 | 8:53 AM ET

    CNBC's Jim Cramer shares his thoughts on the feud between Allergan and Valeant, and weighs in on how a slowdown in Europe would likely impact U.S. markets.

  • Allergan to cut 1,500 employees in restructuring Monday, 21 Jul 2014 | 8:44 AM ET

    Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals. Allergan Inc. has rejected several takeover attempts from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman's Pershing Square Capital Management.

  • US futures lower on Ukraine, Middle East turmoil Monday, 21 Jul 2014 | 8:36 AM ET

    U.S. stock index futures pointed to a lower open on Monday, with investor sentiment subdued due to the ongoing turmoil in Gaza and Ukraine.

  • Allergan posts profit, plans to cut 13% of workforce Monday, 21 Jul 2014 | 8:25 AM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.

  • July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.

  • Early movers: GM, AGN, VRX, HAS, V, MA, IBM & more Monday, 21 Jul 2014 | 8:00 AM ET
    Traders work the floor of the New York Stock Exchange before the closing bell in New York.

    Some of the names on the move ahead of the open.

  • Valeant complains to regulators about Allergan Monday, 21 Jul 2014 | 7:07 AM ET
    Michael Pearson, CEO of Valeant Pharmaceuticals.

    Valeant has complained to regulators that claims made by Allergan to counter a hostile takeover are misleading, sources have told CNBC.

  • Valeant complains to SEC     Monday, 21 Jul 2014 | 7:05 AM ET

    Valeant contends Allergan claims are misleading and manipulative, reports CNBC's Andrew Ross Sorkin with the latest details on the feud between the two companies.

  • July 18- Valeant Pharmaceuticals Inc moved on Friday to blunt a key criticism by takeover target Allergan Inc of its Bausch+ Lomb business by releasing data showing strong sales growth.

  • Midday Glance: Medical Devices companies Friday, 18 Jul 2014 | 1:19 PM ET

    Allergan rose $1.25 or. 8 percent, to $167.07. Baxter International Inc. fell$. 25 or. 3 percent, to $76.00. Boston Scientific Corp. rose$. 18 or 1.4 percent, to $12.64.

  • July 18- Valeant Pharmaceuticals Inc moved on Friday to blunt a key criticism by takeover target Allergan Inc of its Bausch+ Lomb business by releasing data showing strong sales growth.

  • July 17- Allergan Inc, trying to fend off a hostile takeover bid from Valeant Pharmaceuticals International Inc, has thrown up obstacles to a special shareholders meeting, its biggest investor said on Thursday.

  • July 17- Allergan Inc, trying to fend off a hostile takeover bid from Valeant Pharmaceuticals International Inc, has stacked the odds against a special shareholders meeting, its biggest investor said on Thursday.

  • The billionaire investors, who have been at odds over nutrition and diet company Herbalife, made up in public on Wednesday, ending a decade long feud that exploded on cable television 18 months ago.

  • Guess who bro hugged? Yep. Ackman, Icahn Wednesday, 16 Jul 2014 | 5:16 PM ET

    The billionaire activist investors shared the stage during a surprise joint appearance at the Delivering Alpha conference.

  • NEW YORK, July 16- Billionaire investor John Paulson on Wednesday called Valeant Pharmaceuticals International Inc a "very serious acquirer" and predicted that Allergan Inc cannot rebuff the drug maker on its own.

  • Midday Glance: Medical Devices companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Allergan rose$. 59 or. 4 percent, to $164.97. Baxter International Inc. fell$. 23 or. 3 percent, to $76.53. Boston Scientific Corp. rose$. 09 or. 7 percent, to $12.94.

  • Paulson: No end to M&A activity in sight Wednesday, 16 Jul 2014 | 2:37 PM ET

    John Paulson, founder of hedge fund firm Paulson & Co., said corporate M&A activity "will continue for the foreseeable future."

  • Early Glance: Medical Devices companies Wednesday, 16 Jul 2014 | 11:11 AM ET

    Allergan rose$. 09 or. 1 percent, to $164.47. Baxter International Inc. fell$. 09 or. 1 percent, to $76.67. Boston Scientific Corp. rose$. 07 or. 5 percent, to $12.92.